PODGORICA, MONTENEGRO--(Marketwired - Jan 27, 2015) - The Institute of Biomedical Research Corp. (OTC: MRES) is pleased to announce that it has completed the acquisition of Travel Mix Group Inc. Both parties have signed the agreement by which The Institute of Biomedical Research acquires all the outstanding shares of Travel Mix Group in exchange for restricted shares. The Agreement is binding and irrevocable and is effective immediately.

Dr. Drasko Pekovic, President and CEO of the Institute, said, "This new opportunity represents a complete change of direction for the company and the chance to create long lasting shareholder value. We are very excited by the growth prospect provided by TRVEL MIX GROUP moving forward. Our new corporate direction will prove to be an incredible success for all of us."

Boris Golan, CEO of Travel Mix, said, "We have the largest selection of travel services for the lowest prices on line; we are extremely excited about our plans for global expansion in the very near future."

About TRAVELMIX
 Travel Mix Inc. -- Is a Canadian Based online travel Agency with sales & marketing offices throughout Canada and its affiliates in Las Vegas, USA. Providing Canadian, American and International travelers with all possible travel related services online and through our telephone travel agents. Travel Mix offers a real time bookings and reservations on Packaged Vacations, Air Tickets, Last Minute Deals, Car Rentals, Hotel Reservations, Cruises, Travel Insurance, Tickets, Attractions and more! Travel Mix web-site has all travel related information links and all the necessary travel related content. Travel Mix uses Amadeus and Sabre as their main CRS, Softvoyage as their packaged vacation engine and the 5 largest insurance companies for their Travel Insurance. Travel Mix also has a large number of Consolidators connected directly to the booking search engine and other private sources to maintain the lowest price and the widest selection.

www.travelmix.ca

About The Institute of Biomedical Research
 The Institute of Biomedical Research (www.institutebmr.com) is an ambitious biomedical business venture whose activities extend from highly diversified scientific research and sophisticated services research and development, quality control and standardization of pharmaceuticals, (cosmetics and food products) up to major long term biomedical and environmental research projects, as well as the development of new diagnostic technologies and innovative experimental medical treatments. Regulatory certification of new drugs and biomedical products also constitutes important business activities of the Institute. The Institute is essential for the development of Montenegro within the regional and European environment.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although The Institute of Biomedical Research Corp. (the "Company" or "MRES") believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Institute will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's filings with OTCMarkets.com. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.